#USA #Cambridge #gene therapy #ASGCT 2026 #Ring Therapeutics

Ring Therapeutics Unveils Groundbreaking Platforms at ASGCT 2026

In a pivotal moment for the field of gene therapy, Ring Therapeutics® presented innovative new findings on its advanced platforms, the Vector Conjugate and VectorBricks™, during the 29th Annual American Society of Gene & Cell Therapy (ASGCT) conference. This significant event took place in Cambridge, Massachusetts, on May 14, 2026, and the data presented heralds a new era in targeted medicine.

The Innovations of Ring Therapeutics

These new technological advancements by Ring address long-standing challenges in the field of gene and cell therapy. Specifically, the Vector Conjugate platform enhances the delivery of therapeutic oligonucleotides using targetable vectors, while the VectorBricks™ technology focuses on the scalable production of these innovative medicines. Together, they offer exciting possibilities for the treatment of various diseases by improving drug delivery systems.

Dmitriy Bobrovnikov, PhD, the Chief Innovation Officer at Ring Therapeutics, stated, “Our Vector Conjugate platform is designed to carry Orders of Magnitude more payload than traditional antibodies. This includes a variety of therapeutic agents, ranging from small molecules to complex oligonucleotides.” This advancement is crucial for enhancing selective tissue targeting in drug delivery, which is fundamental in tackling challenging medical scenarios like genetic disorders and cancer.

Data Highlights Presented at ASGCT

During the conference, Ring shared key findings from two forms of presentations.

Poster Presentation:

• - Title: Vector Oligonucleotide Carriers (VOCs) - A Platform for Targeted Oligonucleotide Delivery using redosable Viral Capsids.
• - Location: Exhibit and Poster Hall (Halls B2-C), Thursday, May 14, 5:00 - 6:30 PM ET

This study introduced VOCs, showcasing a novel platform for the viral capsid-mediated delivery of oligonucleotides. They achieved notable success through the direct conjugation of synthetic siRNA molecules to recombinant capsid proteins. The results indicated a significant enhancement in the targeted delivery of functional siRNA payloads, demonstrating the potential for precise gene knockdown in target cells.

Oral Presentation:

• - Title: Pilot-Scale Production of In Vitro Assembled Anellovirus Capsids for a Novel Therapeutic Platform
• - Speaker: Sunaina Kiran Prabhu, PhD, Associate Director, Tech Ops at Ring Therapeutics.
• - Location: Room 257AB (Level 2), Thursday, May 14, 4:15 - 4:30 PM ET

This presentation illustrated the VectorBricks™ platform's cost-effective, highly modular capabilities for developing therapeutic applications. Key highlights include the efficient creation of recombinant Anellovirus capsid proteins at high titers, with production capabilities that parallel traditional processes used in the manufacture of monoclonal antibodies. This modular assembly method will enable a diverse range of therapeutic payloads to be effectively encapsulated.

The Future of Gene Therapy with Ring Therapeutics

Ring Therapeutics is at the forefront of a transformative shift in how targeted therapies can be developed and delivered. Their Vector Conjugate platform and VectorBricks™ technology represent substantial advancements over existing methods, unlocking the potential for more effective, customizable treatments for conditions previously deemed challenging to address.

Bobrovnikov aptly summarized the significance of their findings, noting that the enhanced payload capacity of their platforms is essential for accessing new tissue targets, particularly those requiring a higher payload capacity than is typically achievable.

In closing, Ring Therapeutics has set ambitious goals in the therapeutic landscape, and with their innovative approaches, they are paving the way for groundbreaking treatments that hold great promise for patients around the world.

To learn more about Ring Therapeutics and the exciting developments in the field, you can visit their official website Ring Therapeutics.